Polymorphisms within glutathione S-transferase genes (GSTM1, GSTT1, GSTP1) and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia: a case-control study - PubMed (original) (raw)
. 2000 Feb 15;95(4):1222-8.
Affiliations
- PMID: 10666194
Free article
Polymorphisms within glutathione S-transferase genes (GSTM1, GSTT1, GSTP1) and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia: a case-control study
M Stanulla et al. Blood. 2000.
Free article
Abstract
Glutathione S-transferases (GSTs) have been associated with outcome in human cancers treated with cytotoxic chemotherapy. In a case-control study, we investigated the association between polymorphisms within the GSTM1, GSTT1, and GSTP1 genes and risk of relapse in childhood acute lymphoblastic leukemia (ALL). Cases were relapsed patients. Controls were successfully treated patients with a minimum follow-up of 5 years. The null genotype (absence of both alleles) for GSTM1 or GSTT1 conferred a 2-fold (OR = 0.5, 95% CI = 0. 23-1.07, P =.078) and 2.8-fold (OR = 0.36, 95% CI = 0.13-0.99, P =. 048) reduction in risk of relapse, respectively, relative to the presence of the GSTM1 or GSTT1 gene. The GSTP1 Val(105)/Val(105) genotype showed a 3-fold decrease in risk of relapse (OR = 0.33, 95% CI = 0.09-1.23, P =.099) in comparison to the combined category of Ile(105)/Val(105) and Ile(105)/Ile(105 )genotypes. No particular associations with relapse were observed for the GSTP1 polymorphism at codon 114. The risk of relapse when having 1 of the low-risk genotypes (GSTM1 null, GSTT1 null, GSTP1 Val(105)/Val(105)) decreased 1.9-fold (OR = 0.53, 95% CI = 0.24-1.19, P =.123), and the risk when having 2 or 3 low-risk genotypes 3.5-fold (OR = 0.29, 95% CI = 0.06-1.37, P =.118), compared with individuals having no low-risk genotype (P for trend =.005). Our results suggest that polymorphisms within genes of the GST superfamily may be associated with risk of relapse in childhood ALL. (Blood. 2000;95:1222-1228)
Similar articles
- Association of genetic polymorphism of glutathione S-transferase (GSTM1, GSTT1, GSTP1) with bladder cancer susceptibility.
Safarinejad MR, Safarinejad S, Shafiei N, Safarinejad S. Safarinejad MR, et al. Urol Oncol. 2013 Oct;31(7):1193-203. doi: 10.1016/j.urolonc.2011.11.027. Epub 2011 Dec 11. Urol Oncol. 2013. PMID: 22154357 - [Increased frequency of A-G transition at exon 5 of GSTP1 as a genetic risk factor for acute childhood leukaemia].
Zubowska M, Zielińska E, Zmysłowska A, Bodalski J. Zubowska M, et al. Med Wieku Rozwoj. 2004 Apr-Jun;8(2 Pt 1):245-57. Med Wieku Rozwoj. 2004. PMID: 15738600 Polish. - Polymorphisms within glutathione S-transferase genes and initial response to glucocorticoids in childhood acute lymphoblastic leukaemia.
Anderer G, Schrappe M, Brechlin AM, Lauten M, Muti P, Welte K, Stanulla M. Anderer G, et al. Pharmacogenetics. 2000 Nov;10(8):715-26. doi: 10.1097/00008571-200011000-00006. Pharmacogenetics. 2000. PMID: 11186134 - Glutathione s-transferase polymorphisms (GSTM1, GSTP1 and GSTT1) and the risk of acute leukaemia: a systematic review and meta-analysis.
Ye Z, Song H. Ye Z, et al. Eur J Cancer. 2005 May;41(7):980-9. doi: 10.1016/j.ejca.2005.01.014. Eur J Cancer. 2005. PMID: 15862746 Review. - Role of polymorphisms of GSTM1, GSTT1 and GSTP1 Ile105Val in childhood acute lymphoblastic leukemia risk: an updated meta-analysis.
Zhao T, Ma F, Yin F. Zhao T, et al. Minerva Pediatr. 2018 Apr;70(2):185-196. doi: 10.23736/S0026-4946.17.04657-6. Epub 2017 Feb 7. Minerva Pediatr. 2018. PMID: 28176509 Review.
Cited by
- Glutathione S-Transferase Gene Polymorphisms as Predictors of Methotrexate Efficacy in Juvenile Idiopathic Arthritis.
Huljev Frkovic S, Jelusic M, Crkvenac Gornik K, Rogic D, Frkovic M. Huljev Frkovic S, et al. Biomedicines. 2024 Jul 24;12(8):1642. doi: 10.3390/biomedicines12081642. Biomedicines. 2024. PMID: 39200106 Free PMC article. - Genetic Polymorphisms in Glutathione S-Transferase (GST) Gene and Their Correlation with Toxicity of Chemotherapy in Breast Cancer Patients.
Gudur RA, Bhosale SJ, Gudur AK, Datkhile KD. Gudur RA, et al. Asian Pac J Cancer Prev. 2024 Jul 1;25(7):2271-2282. doi: 10.31557/APJCP.2024.25.7.2271. Asian Pac J Cancer Prev. 2024. PMID: 39068558 Free PMC article. - Post-Transplant Cyclophosphamide for the Prevention of Graft-vs.-Host Disease in Allogeneic Hematopoietic Cell Transplantation: A Guide to Management for the Advanced Practitioner.
Kachur E, Patel JN, Morse AL, Moore DC, Arnall JR. Kachur E, et al. J Adv Pract Oncol. 2023 Sep;14(6):520-532. doi: 10.6004/jadpro.2023.14.6.5. Epub 2023 Sep 1. J Adv Pract Oncol. 2023. PMID: 37808076 Free PMC article. Review. - GSTT1 null and rs156697 Polymorphism in GSTO2 Influence the Risk and Therapeutic Outcome of B-Acute Lymphoblastic Leukemia Patients.
Baba SM, Pandith AA, Shah ZA, Geelani SA, Bhat JR, Gul A, Guru SA, El-Serehy HA, Koul AM, Mansoor S. Baba SM, et al. Front Oncol. 2021 Oct 14;11:714421. doi: 10.3389/fonc.2021.714421. eCollection 2021. Front Oncol. 2021. PMID: 34722260 Free PMC article. - GSTM1 and GSTT1 double null genotypes determining cell fate and proliferation as potential risk factors of relapse in children with hematological malignancies after hematopoietic stem cell transplantation.
Jurkovic Mlakar S, Uppugunduri SCR, Nava T, Mlakar V, Golay H, Robin S, Waespe N, Rezgui MA, Chalandon Y, Boelens JJ, Bredius RGM, Dalle JH, Peters C, Corbacioglu S, Bittencourt H, Krajinovic M, Ansari M; paediatric diseases working party of the European society for blood and marrow transplantation. Jurkovic Mlakar S, et al. J Cancer Res Clin Oncol. 2022 Jan;148(1):71-86. doi: 10.1007/s00432-021-03769-2. Epub 2021 Sep 9. J Cancer Res Clin Oncol. 2022. PMID: 34499222 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous